- Company
- Biosimilars Onbevezy·Remsima compete for sales lead in KOR
- by Chon, Seung-Hyun Dec 5, 2024 05:53am
- Biosimilars developed by Celltrion and Samsung Bioepis have been expanding their presence in the domestic market. Samsung Bioepis' Onbevezy has surpassed sales of KRW 10 billion, becoming the top-selling biosimilar developed in South Korea. Since Q3 of last year, Celltrion's Remsima has allowed Onbevezy to take a market-leading position. However
- Policy
- 30-day negotiation window for essential medicines
- by Lee, Tak-Sun Dec 4, 2024 05:57am
- The National Health Insurance Service (NHIS) has started revising guidelines related to the government's initiative to improve the drug pricing system to 'reflect on the new drug innovative value.' First, the NHIS announced to introduce Risk Sharing Agreement (RSA) types and has reduced the time required to negotiate pricing adjustments f
- Company
- Boryung starts in-house producing lung cancer drug 'Alimta'
- by Heo, sung-kyu Dec 4, 2024 05:56am
- As Boryung has started in-house production of 'Alimta (pemetrexed),' a non-small cell lung cancer (NSCLC) treatment that Boryung acquired the sales right in 2022, attention is drawn to the background. Analysis indicates that Boryung aims to take a share of the market worth KRW 20 billion as part of a synergistic strategy for operating a manuf
- Policy
- Legislation of ‘INN prescriptions’ for drugs begin
- by Lee, Jeong-Hwan Dec 4, 2024 05:56am
- The government is promoting legislation to recommend international non-proprietary name prescriptions for national essential medicines and drugs with unstable supply and demand and to encourage the use of 'product name and the international non-proprietary name’ when obtaining a marketing authorization. The bill also includes a provision
- Company
- SK Bioscience wins 2nd trial on pneumococcal patent dispute
- by Kim, Jin-Gu Dec 4, 2024 05:56am
- &160; SK Bioscience has won the second trial of its patent infringement lawsuit against Pfizer over its pneumococcal vaccine, overturning the ruling made in the first trial.&160; The two companies have been engaged in a long-running lawsuit over SK Bioscience's 13-valent pneumococcal vaccine, ‘Skypheumo Prefilled Syringe (Skypheumo).’
- Company
- Sanofi announces entering the RSV vacc. market for children
- by Whang, byung-woo Dec 4, 2024 05:56am
- Sanofi has announced the launch of Beyfortus, an injectable antibody drug to prevent respiratory syncytial virus (RSV) lower respiratory tract disease, for the first time in South Korea. The company aims to take a market share. As clinical practices are in high demand for the vaccine, proactive RSV prevention will become possible following th
- Company
- GSK seeks HIV paradigm shift with long-acting injectable
- by Whang, byung-woo Dec 4, 2024 05:56am
- With the long-acting HIV drug Vocabria+Rekambys combination therapy seeking insurance reimbursement coverage, attention is being paid to whether the drug’s introduction will bring about a shift in the treatment environment. According to industry sources on the 3rd, GSK Korea has completed pharmacoeconomic evaluations for its new HIV dru
- Policy
- 17 drugs receive essential medicine designations
- by Lee, Hye-Kyung Dec 3, 2024 05:53am
- Seventeen medicines that are essential for pediatric patients, cancer patients, and others, but require government support due to unstable supply, have been newly designated as national essential medicines. The Ministry of Food and Drug Safety (MFDS, Yu-Kyung Oh) announced on the 29th that it held a meeting on the stable supply of national es
- Company
- 4 out of 5 pharmas saw export sales expanded
- by Kim, Jin-Gu Dec 3, 2024 05:53am
- Export sales of four out of five pharmaceutical and biotech companies have increased year-over-year (YoY). The net export sales of 28 major pharmaceutical companies increased from KRW 5.3405 trillion to KRW 6.6449 trillion over a year, up 25.6%. Samsung Biologics' export sales increased by over KRW 600 billion. Export sales of Celltrion
- Policy
- Janssen’s Tremfya’s price cut 2yrs due to increased use
- by Lee, Tak-Sun Dec 3, 2024 05:52am
- The upper limit price of Tremfya, Janssen's autoimmune disease treatment, is expected to be reduced under the price-volume agreement system for the second consecutive year.&160; According to industry sources, the National Health Insurance Service and Janssen recently finalized PVA negotiations for the reimbursement of Tremfya on the 1s
